# Vertex Pharmaceuticals Incorporated  Share Price Target ‘$473.61’, now .7% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-share-price-target-473.61-now.7-upside-potential/4121163979
- Published: 2024-07-05T15:20:48+01:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) now have 26 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between $577.00 
and $325.00 and has a mean share price target at $473.61. (at the time of writing).
Given that the stocks previous close was at $470.28 this would indicate that there
is a potential upside of .7%. It’s also worth noting that there is a 50 day moving
average of $446.71 and the 200 moving average now moves to $406.70. The company 
has a market capitalization of 122.06B. The stock price is currently at: $473.02
USD

 The potential market cap would be $122,928,547,355 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.66, revenue per share of $39.49
and a 12.82% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: